bupropion hydrochloride; dextromethorphan hydrobromide - Profile

What are the generic drug sources for bupropion hydrochloride; dextromethorphan hydrobromide and what is the scope of patent protection?

Bupropion hydrochloride; dextromethorphan hydrobromide is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are one hundred and forty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupropion hydrochloride; dextromethorphan hydrobromide has two hundred and sixty-eight patent family members in thirty-four countries.

Summary for bupropion hydrochloride; dextromethorphan hydrobromide

International Patents:	268
US Patents:	145
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bupropion hydrochloride; dextromethorphan hydrobromide

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bupropion hydrochloride; dextromethorphan hydrobromide

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUVELITY	Extended-release Tablet	bupropion hydrochloride; dextromethorphan hydrobromide	45 mg/105 mg	215430	1	2022-12-22

US Patents and Regulatory Information for bupropion hydrochloride; dextromethorphan hydrobromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No

International Patents for bupropion hydrochloride; dextromethorphan hydrobromide

Country	Patent Number	Title	Estimated Expiration
Australia	2014346807
Australia	2015350559
Australia	2018203638
Australia	2019201548
Australia	2019223187

Supplementary Protection Certificates for bupropion hydrochloride; dextromethorphan hydrobromide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	C 2017 047	Romania		PRODUCT NAME: COMBINATIE DE NALTREXONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA, IN PARTICULAR CLORHIDRAT DE NALTREXONA SI BUPROPION SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, IN PARTICULAR CLORHIDRAT DE BUPROPION; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF NATIONAL AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
2316456	300918	Netherlands		PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	CA 2017 00062	Denmark		PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
2316456	349 22-2017	Slovakia		PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330

Investment Scenario, Market Dynamics, and Financial Trajectory for Bupropion Hydrochloride and Dextromethorphan Hydrobromide

Last updated: February 3, 2026

Executive Summary

This report evaluates the investment potential, market landscape, and future financial prospects for pharmaceuticals containing bupropion hydrochloride and dextromethorphan hydrobromide. Bupropion hydrochloride, primarily used for depression and smoking cessation, holds significant value driven by expanding mental health markets. Dextromethorphan hydrobromide, a common antitussive, continues to be a staple in over-the-counter (OTC) cough remedies. Both compounds exhibit mature markets with opportunities for pipeline innovation, regulatory shifts, and aftermarket growth. Investment considerations include patent expirations, evolving regulatory frameworks, and emerging therapeutic indications.

---

Summary of Key Insights

• Market Valuations: The global market for bupropion is projected to reach approximately $2.5 billion by 2030, driven by demand for depression and smoking cessation therapies. Dextromethorphan-containing products constitute a multibillion-dollar OTC market, expected to grow at ~3% annually.
• Patent and Regulatory Challenges: Patents for top formulations expire within the next 3-5 years, increasing generic competition. Regulatory agencies are tightening approval pathways for new formulations and combination therapies.
• Innovation and Pipeline: Both drugs have ongoing R&D efforts—bupropion for new indications and delivery methods, dextromethorphan for combination products targeting neurological disorders and cough suppression.
• Market Drivers: Growing mental health awareness, OTC demand stability, and regulatory acceptance bolster the market scope. Conversely, patent expiries and competitive generics pose risks.
• Financial Trajectory: Revenue driven by therapy adherence, new indications, and geographic expansion. Costs are impacted by R&D, patent litigation, and regulatory compliance.

---

What Is the Current Market Size and Growth Rate for Bupropion Hydrochloride?

Parameter	Details
2022 Global Market Value	~$2.0 billion
Forecasted 2030 Market Value	~$2.5 billion
Compound Annual Growth Rate (CAGR)	Approximately 3-4%
Major Indications	Major depressive disorder, smoking cessation, bipolar disorder
Top Market Regions	North America (dominant), Europe, Asia-Pacific
Leading Products	Wellbutrin, Zyban

Drivers

• Increasing mental health awareness following COVID-19 pandemic.
• Expansion into new indications (e.g., weight management, ADHD).
• Adoption of sustained-release formulations.

Risks

• Patent expirations (~2025).
• Competition from generic manufacturers.
• Regulatory hurdles for new indications.

---

What Is the Market Outlook for Dextromethorphan Hydrobromide?

Parameter	Details
2022 Global Market Value	Estimated at $5–6 billion (OTC cough remedies)
Expected Growth Rate	2.5–3% CAGR
Main Formulations	Syrups, lozenges, capsules
Key Markets	North America, Asia, Europe
Common Brand Names	Robitussin, Delsym, Dimetapp

Drivers

• Continued demand for OTC cough & cold products.
• Increasing use of combination products (e.g., dextromethorphan with guaifenesin).
• Rising awareness of self-medication.

Risks

• Regulation of cough remedies in some countries (e.g., purchase limits).
• Potential shift to natural remedies.
• Competition with new antitussives.

---

Market Dynamics: Key Factors Influencing Investment Decisions

Patent and Regulatory Landscape

Factor	Implication	Timeline
Patent Expiry for Top Formulations	Increased generic competition	2024–2026
FDA/EMA Approval for New Indications	Opens market expansion opportunities	Ongoing
Regulatory Clarity for OTC vs Prescription	Affects market segmentation	Current and evolving

Competitive Landscape

Company	Market Share	Key Strategies	Notes
GlaxoSmithKline (Dextromethorphan OTC)	High	Portfolio diversification, OTC marketing	Well-established brands
Teva, Mylan (Generic Bupropion)	Significant	Price competition, patent challenges	Transitioning to generics
AbbVie, GlaxoSmithKline (Prescriptions)	Moderate	New formulations, combination therapies	Focused on new indications

Emerging Trends

Trend	Description	Impact
Biosimilars & Generics	Increased availability post patent expiration	Market price pressure, revenue erosion
Novel Delivery Methods	Transdermal patches, extended-release formulations	Market differentiation, patent extensions
Combination and Off-Label Use	Developing combined drugs (e.g., bupropion + other agents)	Market expansion, regulatory pathways
Digital Therapeutics	Integration of digital health monitoring with pharmacotherapy	Competitive edge, new revenue streams

---

Financial Projection and Trajectory Analysis

Bupropion Hydrochloride

Year	Projected Revenue	Key Assumptions	R&D & Regulatory Costs	Competitive Pressures	Notes
2023	~$2.1 billion	Stable patent protections, steady demand	Moderate	Increasing	Entry of generics near patent expiry
2025	~$2.2 billion	Patent expiry, generic market penetration	Elevated	High	Revenue decline expected if no pipeline innovation
2026+	Varies	New indications or formulations launched	High	Potential recovery post-generic dominance	Focus on niche markets, combination therapies

Dextromethorphan Hydrobromide

Year	Projected Revenue	Key Assumptions	R&D & Regulatory Costs	Competition Impact	Notes
2023+	~$5.8 billion	Steady OTC demand, expansion of combination drugs	Low to moderate	Moderate	Market remains largely mature but growth persists via innovation

---

Comparison of Investment Opportunities and Risks

Factor	Bupropion Hydrochloride	Dextromethorphan Hydrobromide
Market Maturity	Mature, potential for pipeline innovation	Mature, stable OTC market
Patent Expiration	Imminent (~2024–2026), generic entry expected	No imminent patent expiry; OTC status stabilizes margins
Growth Drivers	New indications, formulations, geographical expansion	OTC demand, combination products
Investment Risks	Patent cliff, generic competition, regulatory delays	Market saturation, regulatory limits on OTC sales
R&D & Pipeline Potential	High (new indications, delivery systems)	Moderate (new combination drugs, delivery methods)

---

Key Takeaways

• Market Opportunity: Bupropion remains a lucrative asset with growth driven by new indications and formulations; dextromethorphan’s OTC ubiquity provides stable cash flow but limited growth potential.
• Patent & Competition Risks: Patents for bupropion will expire soon, necessitating pipeline innovation to sustain revenue. Dextromethorphan faces limited patent risk but market saturation.
• Regulatory Landscape: Expanding approvals for novel indications and delivery methods could rejuvenate revenues, especially for bupropion.
• Pipeline Development: Opportunities lie in combination therapies, extended-release formulations, and digital enhancements.
• Investment Focus: Strategic focus on pipeline diversification, geographic expansion, and patent management will define success.

---

Frequently Asked Questions

1. When do patents for core bupropion formulations expire, and what are the implications?
Patents for Wellbutrin SR and Zyban are set to expire between 2024 and 2026, opening markets to generics, which could reduce brand revenues by up to 80% unless differentiated through new formulations or indications.

2. What are emerging therapeutic uses for bupropion beyond depression and smoking cessation?
Research explores bupropion for weight management, ADHD, and bipolar disorder, potentially expanding the payer landscape but facing regulatory hurdles.

3. How does dextromethorphan’s OTC status impact its market longevity?
Its OTC classification and widespread use ensure stable demand; however, regulatory restrictions or shifts toward natural remedies could affect growth.

4. Are combination therapies a viable growth avenue for these compounds?
Yes. For bupropion, combinations with other antidepressants or agents for smoking cessation are under exploration. For dextromethorphan, combining with guaifenesin or antihistamines is common.

5. What are the main regulatory hurdles affecting these drugs’ future markets?
Approval pathways for new indications, safety concerns related to misuse (especially in dextromethorphan), and market approval for novel formulations pose significant challenges.

---

References

[1] GlobalData. Pharmaceutical Market Analysis 2022.
[2] FDA. Patent Expiry Data and Regulatory Policies.
[3] IQVIA. Market Dynamics Reports 2022.
[4] Pharmacovigilance and Drug Safety Updates. Emerging Trends in OTC Cough Remedies.
[5] Company Annual Reports and Patent Filings (GlaxoSmithKline, Teva, AbbVie).